Prostate-Specific Antigen (PSA) Screening for Early Detection of Prostate Cancer: An Evidence-Based Analysis
Literature Review
DOI:
https://doi.org/10.55175/cdk.v53i07.1981Keywords:
Early detection, prostate cancer, PSA screening, screening guidelinesAbstract
Introduction: Prostate-specific antigen (PSA) screening has transformed the early detection of prostate cancer, yet its widespread implementation remains controversial due to concerns over overdiagnosis, overtreatment, and questionable mortality benefit. This article evaluates the contemporary evidence regarding the benefits and harms of PSA-based screening, synthesizing findings from major clinical trials, cost-effectiveness analyses, and international guidelines. Methods: An evidence-based analysis using data from pivotal trials such as ERSPC, along with recent meta-analyses, biomarker advancements, MRI-based protocols, and national screening guidelines from the USPSTF, EAU, NCCN, and others. Results: PSA screening may reduce prostate cancer-specific mortality, particularly in men aged 55–69 years. It facilitates early detection, enhances access to curative therapies, and promotes broader health engagement. However, it carries significant risks, including overdiagnosis of indolent tumors, overtreatment-related morbidity, false positives, psychological distress, and economic burden. Mortality outcomes across studies remain inconsistent, prompting a shift toward personalized, risk-adapted screening guided by age, comorbidities, family history, biomarkers (e.g., PHI, 4Kscore), and multiparametric MRI. Conclusion: PSA screening should not be universally applied but rather employed through shared decision-making and individualized risk assessment. Continued research is warranted to optimize outcomes and inform equitable screening policies, particularly in resource-limited settings.
Downloads
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. doi: 10.3322/caac.21660
Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, et al. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force review. J Clin Oncol. 2012;30(21):2581–4. doi: 10.1200/JCO.2011.40.4327.
Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA. 2014;311(11):1143–9. doi: 10.1001/jama.2014.2085
Cornford P, Van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer—2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86(2):148–63. doi: 10.1016/j.eururo.2024.03.027
Wilt TJ, Scardino PT, Carlsson SV, Basch E. Prostate-specific antigen screening in prostate cancer: perspectives on the evidence. J Natl Cancer Inst. 2014;106(3):dju010. doi: 10.1093/jnci/dju010
Schroder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized european study. N Engl J Med. 2009;360(13):1320–8. doi: 10.1056/NEJMoa0810084.
US Preventive Services Task Force; Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901–13. doi: 10.1001/jama.2018.3710.
Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8(4):268–78. doi: 10.1038/nrc2351.
Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA. 2005;294(1):66–70. doi: 10.1001/jama.294.1.66.
Loeb S. Evidence-based versus personalized prostate cancer screening: using baseline prostate-specific antigen measurements to individualize screening. J Clin Oncol. 2016;34(23):2684–6. doi: 10.1200/JCO.2016.68.2138.
Guo Y, Dong X, Mao S, Yang F, Wang R, Ma W, et al. Causes of death after prostate cancer diagnosis: a population-based study. Oxid Med Cell Longev. 2022;2022(1):8145173. doi: 10.1155/2022/8145173.
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415–24. doi: 10.1056/NEJMoa1606220.
Eklund M, Jaderling F, Discacciati A, Bergman M, Annerstedt M, Aly M, et al. MRI-targeted or standard biopsy in prostate cancer screening. N Engl J Med. 2021;385(10):908–20. doi: 10.1056/NEJMoa2100852.
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374–83. doi: 10.1093/jnci/djp001
Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425–37. doi: 10.1056/NEJMoa1606221.
Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, et al. Active surveillance for prostate cancer: a systematic review of clinico-pathologic variables and biomarkers for risk stratification. Eur Urol. 2015;67(4):619–26. doi: 10.1016/j.eururo.2014.10.010.
Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125–32. doi: 10.1093/jnci/djr500.
Pinsky PF, Prorok PC, Kramer BS. Prostate cancer screening — a perspective on the current state of the evidence. N Engl J Med. 2017;376(13):1285–9. doi: 10.1056/NEJMsb1616281.
Volk RJ, Spann SJ, Cass AR, Hawley ST. Patient education for informed decision making about prostate cancer screening: a randomized controlled trial with 1-year follow-up. Ann Fam Med. 2003;1(1):22–8. doi: 10.1370/afm.7.
Heijnsdijk EAM, Carvalho TM de, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, et al. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J Natl Cancer Inst. 2015;107(1):dju366. doi: 10.1093/jnci/dju366.
Shteynshlyuger A, Andriole GL. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the european study of screening for prostate cancer. J Urol. 2011;185(3):828–32. doi: 10.1016/j.juro.2010.10.079.
Klotz L. Prostate cancer overdiagnosis and overtreatment. Curr Opin Endocrinol Diabetes Obes. 2013;20(3):204–9. doi: 10.1097/MED.0b013e328360332a.
Lillard JW, Moses KA, Mahal BA, George DJ. Racial disparities in black men with prostate cancer: a literature review. Cancer. 2022;128(21):3787–95. doi: 10.1002/cncr.34433.
Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, et al. NCCN guidelines insights: prostate cancer, version 1.2021: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2021;19(2):134–43. doi: 10.6004/jnccn.2021.0008.
Bell N, Gorber SC, Shane A, Joffres M, Singh H, Dickinson J, et al. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ. 2014;186(16):1225–34. doi: 10.1503/cmaj.140703.
Dasgupta P, Davis J, Hughes S. NICE guidelines on prostate cancer 2019. BJU Int. 2019;124(1):1. doi: 10.1111/bju.14815.
Stephan C. Prostate cancer: WHO standardization of PSA tests: clinical consequences. Nat Rev Urol. 2009;6(6):303–5. doi: 10.1038/nrurol.2009.94.
Schroder FH, Hugosson J, Roobol MJ, Tammela TLJ, Zappa M, Nelen V, et al. The European randomized study of screening for prostate cancer–prostate cancer mortality at 13 years of follow-up. Lancet 2014;384(9959):2027–35. doi: 10.1016/S0140-6736(14)60525-0.
Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The prostate, lung, colorectal and ovarian (PLCO) cancer screening trial of the National Cancer Institute: history, organization, and status. Controlled Clin Trials. 2000;21(6):251S–72S. doi: 10.1016/s0197-2456(00)00097-0.
Ferro M, Bruzzese D, Perdona S, Marino A, Mazzarella C, Peruolo G, et al. Prostate health index (Phi) and prostate cancer antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2–10 ng/ml. PLoS One. 2013;8(7):e67687. doi: 10.1371/journal.pone.0067687.
Voigt JD, Dong Y, Linder V, Zappala S. Use of the 4Kscore test to predict the risk of aggressive prostate cancer prior to prostate biopsy: overall cost savings and improved quality of care to the us healthcare system. Rev Urol. 2017;19(1):1–10. PMID: 28522924.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ilham Saptia Nugraha
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
